Phase II BGG492 Capsule Extension for Partial Epilepsy

Phase 2

Completed

• Conditions: Partial Onset Seizures
• Interventions: Drug: BGG492

• Registration Number: NCT01338805
• Lead Sponsor: Novartis Pharmaceuticals

Brief Summary

This long-term extension study will assess the safety, tolerability and efficacy of BGG492 as adjunctive treatment in patients with partial onset seizures.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2011-04-15
• Study First Submitted QC: 2011-04-18
• Study First Posted: 2011-04-20
• Study Start: 2011-06
• Primary Completion: 2012-07
• Study Completion: 2012-07
• Status Verified: 2016-03
• Disposition First Submitted: 2016-03-22
• Disposition First Submitted QC: 2016-03-22
• Disposition First Posted: 2016-04-25
• Last Update Submitted: 2021-03-02
• Last Update Posted: 2021-03-05

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 56

Inclusion Criteria

• Completed study CBGG492A2207, cooperated with the study procedures and did not experience persistent tolerability issues
• Outpatients ≥ 45 kg (99 lb) of weight
• Patient would like to continue BGG492 treatment and the investigator believes a reasonable benefit from the long-term administration of BGG492 may be expected
• Treated with a stable dose of one or a maximum of three licensed Antiepileptic drugs (AEDs)and are known to take their medication(s) as directed
• Will make themselves available for the study period and are able to record seizures and report adverse events themselves or have a caregiver who can record and report the events
• Provided written informed consent before any extension assessment is performed

Exclusion Criteria

• Status epilepticus or seizure clusters occurring during study CBGG492A2207 or in the period between the end of study the double blind study and the start of study CBGG492A2212 for patients experiencing a treatment gap
• Have been treated with:
• Felbamate, unless treatment has been continuous for ≥ 2 years
• Vigabatrin during the 26 weeks prior to the first dose of open-label medication in the extension study
• Monoamine oxidase (MAO) inhibitors, tricyclic-antidepressants and narcotic analgesics
• L-Dopa formulations
• Use of concomitant medication that are potential inhibitors of Organic anion-transporting polypeptide (OATP) transporters
• No physical examination changes suggestive of progressive neurological changes during Study CBGG492A2207
• Used another investigational drug (other than BGG492) either at the time of enrollment in this extension study or within 5 half-lives prior to enrollment in this extension study
• History of hypersensitivity to the study drug or to drugs of similar chemical classes (e.g. sulfonamides) or had multiple drug allergies or one or more severe drug reactions to an Antiepileptic drugs (AEDs), including dermatological reactions
• Pregnant or nursing (lactating) women

Other protocol-defined inclusion/exclusion criteria may apply

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
BGG492	BGG492	hard gelatin capsule for oral administration at 50 mg TID, 100 mg TID or 150 mg TID

Primary Outcome Measures

Name	Time	Method
To evaluate the long-term safety and tolerability of BGG492 capsules during the maintenance period in patients suffering from partial onset seizures	38 weeks	By measuring the number and percent of patients having any AE (advent event) by primary system organ class and/or preferred term.; By laboratory, vital sign, and ECG data, summary statistics of values and change from baseline

Secondary Outcome Measures

Name	Time	Method
Seizure counts: To evaluate the maintenance of efficacy and safety as assessed in percent change of seizure frequency of BGG492 capsules from the original Baseline Period to the Open-label Extension Maintenance Phase.	38 weeks
To evaluate long-term efficacy and safety by summarizing the number and percentage of patients who discontinue due to unsatisfactory therapeutic response effect and for all other reasons.	30 weeks
Responder rate: To evaluate the maintenance of efficacy by the change in responder rate and numbers of patients becoming seizure free from the original Baseline Period to the Open-label Extension Maintenance Phase.	38 weeks
To evaluate the efficacy over time by the change in partial seizure frequency original Baseline Period in the double-blind study CBGG492A2207 to the Open-label Extension Maintenance Phase.	38 weeks

Trial Locations

Locations (1)

Novartis Investigative Site; 🇸🇰 Kosice, Slovakia